This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Primary progressive freezing gait (PPFG) is a rare progressive neurologic disorder that primarily affects gait, initially resulting in freezing of gait (FOG) and later in postural instability, without other typical parkinsonian features.1 Response to dopaminergic medications is poor, and no satisfactory treatment is yet available for this condition.1 We now report that duloxetine, a new serotonin and norepinephrine reuptake inhibitor (SNRI), provides sustained improvement in a patient with PPFG.
Level of evidence.
This case report provides Class IV evidence that duloxetine, 60 mg/day, decreased the number and severity of FOG episodes in PPFG disorder.
Case report.
A 58-year-old man came to our attention, complaining of progressive gait difficulties that had started 10 months before and led to falls and fear of falling. At our first examination, he presented with FOG consisting mainly of start hesitation, turning hesitation, and narrow hesitation, which deeply affected his daily activities as revealed by a FOG questionnaire (FOG-Q) score of 18 of 242 (video, segment A, on the Neurology® Web site at www. neurology.org). Cutaneous plantar responses were in extension bilaterally, and he had postural instability. …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen